Children's Health Defense Merck is paying $9.2 billion to acquire a drug company primarily for an experimental antiviral flu-prevention drug, marketed specifically as “not a vaccine.”
TrialSite News reported that Merck’s move to acquire Cidara Therapeutics marks a “strategic pivot” toward long-acting antivirals as demand for traditional flu vaccines drops amid failure to match the circulating flu strain.
Daniel O’Connor, founder and CEO of TrialSite News, told The Defender:
“Whether industry leaders admit it publicly or not, Merck’s pivot reflects a market transformed by vaccine fatigue. After years of polarized debate and fluctuating efficacy, long-acting antivirals could be emerging as a politically safer, commercially scalable alternative — and Merck clearly wants to lead that post-vaccine era.”
Merck said in a press release that it will acquire Cidara via a subsidiary for $221.50 per share in cash — more than double the company’s last closing price, CNBC reported. The deal is expected to close in early 2026…
READ FULL ARTICLE HERE… (childrenshealthdefense.org)
Home | Caravan to Midnight (zutalk.com)
Be First to Comment